Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free EXOZ Stock Alerts

eXoZymes (EXOZ) Financials

eXoZymes logo
$5.69 -0.53 (-8.59%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for eXoZymes

Annual Income Statements for eXoZymes

This table shows eXoZymes' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.04 -5.86 -9.16
Consolidated Net Income / (Loss)		 -2.04 -5.86 -9.16
Net Income / (Loss) Continuing Operations		 -2.04 -5.86 -9.16
Total Pre-Tax Income 		-2.00 -5.86 -9.26
Total Operating Income		 -1.80 -5.93 -9.72
Total Gross Profit		 -0.53 -2.53 -3.64
Total Revenue		 0.07 0.00 0.00
Operating Revenue		 0.07 0.00 0.00
Total Cost of Revenue		 0.60 2.53 3.64
Operating Cost of Revenue		 0.60 2.53 3.64
Total Operating Expenses		 1.27 3.40 6.08
Selling, General & Admin Expense		 0.72 1.50 2.28
Research & Development Expense		 0.53 1.87 3.71
Other Operating Expenses / (Income)		 0.02 0.04 0.10
Total Other Income / (Expense), net		 -0.20 0.07 0.45
Interest & Investment Income		 0.00 0.08 0.36
Other Income / (Expense), net		 -0.20 -0.01 0.09
Income Tax Expense		 0.04 0.00 -0.11
Basic Earnings per Share		 ($0.33) ($0.89) ($1.09)
Weighted Average Basic Shares Outstanding		 6.25M 6.56M 8.38M
Diluted Earnings per Share		 ($0.33) ($0.89) ($1.09)
Weighted Average Diluted Shares Outstanding		 6.25M 6.56M 8.38M
Weighted Average Basic & Diluted Shares Outstanding		 - 8.37M 8.48M

Quarterly Income Statements for eXoZymes

This table shows eXoZymes' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -0.52 -1.01 -1.36 -1.66 -1.84 -1.86 -2.36 -2.29 -2.66 -2.37
Consolidated Net Income / (Loss)		 -0.52 -1.01 -1.36 -1.66 -1.84 -1.86 -2.36 -2.29 -2.66 -2.37
Net Income / (Loss) Continuing Operations		 -0.52 -1.01 -1.36 -1.66 -1.84 -1.86 -2.36 -2.29 -2.66 -2.37
Total Pre-Tax Income 		-0.52 -1.01 -1.36 -1.66 -1.84 -1.86 -2.36 -2.29 -2.76 -2.37
Total Operating Income		 -0.39 -1.01 -1.33 -1.61 -1.98 -1.95 -2.55 -2.52 -2.70 -2.39
Total Gross Profit		 -0.12 -0.39 -0.73 -0.55 -0.86 -0.61 -1.07 -0.85 -1.11 -0.83
Total Revenue		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.12 0.39 0.73 0.55 0.86 0.61 1.07 0.85 1.11 0.83
Operating Cost of Revenue		 0.12 0.39 0.73 0.55 0.86 0.61 1.07 0.85 1.11 0.83
Total Operating Expenses		 0.27 0.62 0.60 1.07 1.12 1.34 1.48 1.68 1.59 1.56
Selling, General & Admin Expense		 0.24 0.34 0.35 0.33 0.48 0.74 0.63 0.45 0.45 0.42
Research & Development Expense		 0.03 0.28 0.24 0.72 0.63 0.58 0.80 1.22 1.11 1.12
Other Operating Expenses / (Income)		 0.01 0.00 0.01 0.02 0.01 0.03 0.04 0.01 0.02 0.01
Total Other Income / (Expense), net		 -0.13 0.00 -0.03 -0.04 0.15 0.09 0.19 0.24 -0.06 0.02
Interest & Investment Income		 - 0.00 -0.03 -0.04 0.15 0.09 0.08 0.06 0.13 0.01
Other Income / (Expense), net		 -0.13 - 0.00 0.00 - 0.00 0.11 0.18 - 0.00
Income Tax Expense		 0.00 0.00 0.00 0.00 -0.00 0.00 0.00 0.00 -0.11 0.00
Basic Earnings per Share		 ($0.08) ($0.16) ($0.22) ($0.27) ($0.24) ($0.22) ($0.28) ($0.27) ($0.32) ($0.28)
Weighted Average Basic Shares Outstanding		 6.25M 6.25M 6.25M 6.25M 6.56M 8.37M 8.38M 8.39M 8.38M 8.46M
Diluted Earnings per Share		 ($0.08) ($0.16) ($0.22) ($0.27) ($0.24) ($0.22) ($0.28) ($0.27) ($0.32) ($0.28)
Weighted Average Diluted Shares Outstanding		 6.25M 6.25M 6.25M 6.25M 6.56M 8.37M 8.38M 8.39M 8.38M 8.46M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 6.25M 8.37M 8.37M 8.39M 8.39M 8.48M 8.48M

Annual Cash Flow Statements for eXoZymes

This table details how cash moves in and out of eXoZymes' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.49 9.65 -6.68
Net Cash From Operating Activities		 -1.18 -8.51 -6.50
Net Cash From Continuing Operating Activities		 -1.18 -8.51 -6.50
Net Income / (Loss) Continuing Operations		 -2.04 -5.86 -9.16
Consolidated Net Income / (Loss)		 -2.04 -5.86 -9.16
Depreciation Expense		 0.20 0.27 0.29
Amortization Expense		 -0.05 -0.05 -0.05
Non-Cash Adjustments To Reconcile Net Income		 0.70 -3.08 2.01
Changes in Operating Assets and Liabilities, net		 0.02 0.23 0.41
Net Cash From Investing Activities		 -0.31 -0.36 -0.15
Net Cash From Continuing Investing Activities		 -0.31 -0.36 -0.15
Purchase of Property, Plant & Equipment		 -0.29 -0.40 -0.17
Other Investing Activities, net		 -0.02 0.04 0.02
Net Cash From Financing Activities		 1.00 19 -0.03
Net Cash From Continuing Financing Activities		 1.00 19 -0.03
Repayment of Debt		 0.80 3.98 0.00
Issuance of Common Equity		 0.00 15 0.00
Other Financing Activities, net		 - 0.00 -0.03
Cash Interest Paid		 - 0.00 0.01
Cash Income Taxes Paid		 0.06 0.00 0.00

Quarterly Cash Flow Statements for eXoZymes

This table details how cash moves in and out of eXoZymes' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.41 0.05 0.04 0.08 9.49 -1.21 -1.53 -1.89 -2.06 -1.59
Net Cash From Operating Activities		 -0.78 0.28 -2.54 -0.54 -5.71 -1.13 -1.54 -1.86 -1.97 -1.52
Net Cash From Continuing Operating Activities		 -0.78 0.28 -2.54 -0.54 -5.71 -1.13 -1.54 -1.86 -1.97 -1.52
Net Income / (Loss) Continuing Operations		 -1.10 -1.01 -1.36 -1.66 -1.84 -1.86 -2.36 -2.29 -2.66 -2.37
Consolidated Net Income / (Loss)		 -1.10 -1.01 -1.36 -1.66 -1.84 -1.86 -2.36 -2.29 -2.66 -2.37
Depreciation Expense		 0.06 0.06 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07
Amortization Expense		 - -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01
Non-Cash Adjustments To Reconcile Net Income		 0.44 1.47 -0.86 0.22 -3.92 0.32 0.54 0.46 0.69 0.53
Changes in Operating Assets and Liabilities, net		 -0.13 -0.23 -0.37 0.84 -0.00 0.34 0.22 -0.09 -0.07 0.25
Net Cash From Investing Activities		 -0.11 -0.14 -0.04 0.03 -0.21 -0.03 -0.03 -0.01 -0.07 -0.06
Net Cash From Continuing Investing Activities		 -0.11 -0.14 -0.04 0.03 -0.21 -0.03 -0.03 -0.01 -0.07 -0.06
Purchase of Property, Plant & Equipment		 -0.11 -0.15 -0.04 - -0.21 -0.03 -0.05 -0.01 -0.07 -0.06
Net Cash From Financing Activities		 0.49 -0.09 2.62 0.59 15 -0.04 0.04 -0.02 -0.01 -0.01
Net Cash From Continuing Financing Activities		 0.49 -0.09 2.62 0.59 15 -0.04 0.04 -0.02 -0.01 -0.01
Repayment of Debt		 0.29 0.00 2.64 0.58 0.75 -0.04 0.04 - - 0.00
Other Financing Activities, net		 - -0.09 -0.02 0.00 0.11 0.00 - -0.02 -0.01 -0.01
Cash Interest Paid		 - 0.00 - - - 0.00 0.00 0.00 0.00 0.00

Annual Balance Sheets for eXoZymes

This table presents eXoZymes' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 3.56 13 5.97
Total Current Assets		 1.21 11 3.94
Cash & Equivalents		 0.07 9.72 3.04
Prepaid Expenses		 0.26 0.36 0.38
Other Current Assets		 0.88 0.74 0.52
Plant, Property, & Equipment, net		 0.75 0.88 0.76
Total Noncurrent Assets		 1.59 1.33 1.27
Noncurrent Note & Lease Receivables		 - 0.00 0.11
Noncurrent Deferred & Refundable Income Taxes		 - 0.00 0.11
Other Noncurrent Operating Assets		 1.59 1.33 1.05
Total Liabilities & Shareholders' Equity		 3.56 13 5.97
Total Liabilities		 3.94 2.61 2.57
Total Current Liabilities		 2.42 1.33 1.57
Accounts Payable		 0.70 0.92 1.24
Other Current Liabilities		 1.67 0.41 0.33
Total Noncurrent Liabilities		 1.53 1.28 1.01
Capital Lease Obligations		 - 0.00 0.06
Other Noncurrent Operating Liabilities		 1.53 1.28 0.94
Total Equity & Noncontrolling Interests		 -0.38 10 3.40
Total Preferred & Common Equity		 -0.38 10 3.40
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 -0.38 10 3.40
Common Stock		 5.70 22 25
Retained Earnings		 -6.08 -12 -21

Quarterly Balance Sheets for eXoZymes

This table presents eXoZymes' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 3.56 12 9.68 7.72 4.02
Total Current Assets		 1.42 9.42 7.53 5.61 2.09
Cash & Equivalents		 0.23 8.51 6.99 5.10 1.44
Prepaid Expenses		 0.63 0.31 0.29 0.20 0.34
Other Current Assets		 0.55 0.60 0.26 0.30 0.30
Plant, Property, & Equipment, net		 0.74 0.84 0.82 0.76 0.75
Total Noncurrent Assets		 1.40 1.26 1.32 1.35 1.18
Noncurrent Note & Lease Receivables		 - - 0.13 0.12 0.09
Noncurrent Deferred & Refundable Income Taxes		 - - - 0.11 0.11
Other Noncurrent Operating Assets		 1.40 1.26 1.19 1.12 0.98
Total Liabilities & Shareholders' Equity		 3.56 12 9.68 7.72 4.02
Total Liabilities		 7.16 2.64 2.44 2.34 2.49
Total Current Liabilities		 5.80 1.44 1.22 1.24 1.58
Accounts Payable		 0.91 1.07 0.93 0.90 1.23
Other Current Liabilities		 4.89 0.37 0.29 0.33 0.35
Total Noncurrent Liabilities		 1.36 1.20 1.22 1.11 0.91
Capital Lease Obligations		 - - 0.09 1.00 0.05
Other Noncurrent Operating Liabilities		 1.36 1.20 1.14 0.10 0.86
Total Equity & Noncontrolling Interests		 -3.60 8.88 7.24 5.37 1.53
Total Preferred & Common Equity		 -3.60 8.88 7.24 5.37 1.53
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -3.60 8.88 7.24 5.37 1.53
Common Stock		 6.51 23 23 24 25
Retained Earnings		 -10 -14 -16 -18 -23

Annual Metrics And Ratios for eXoZymes

This table displays calculated financial ratios and metrics derived from eXoZymes' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 6,252,349.00 8,387,250.00
DEI Adjusted Shares Outstanding		 0.00 6,252,349.00 8,387,250.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.94 -1.09
Growth Metrics		 - - -
Revenue Growth		 0.00% -100.00% 0.00%
EBITDA Growth		 0.00% -209.32% -64.04%
EBIT Growth		 0.00% -197.51% -62.11%
NOPAT Growth		 0.00% -230.25% -63.79%
Net Income Growth		 0.00% -187.55% -56.26%
EPS Growth		 0.00% -169.70% -22.47%
Operating Cash Flow Growth		 0.00% -620.29% 23.56%
Free Cash Flow Firm Growth		 0.00% 0.00% -22.95%
Invested Capital Growth		 0.00% 255.59% -39.79%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -7.03%
EBIT Q/Q Growth		 0.00% 0.00% -6.92%
NOPAT Q/Q Growth		 0.00% 0.00% -7.91%
Net Income Q/Q Growth		 0.00% 0.00% -9.82%
EPS Q/Q Growth		 0.00% 0.00% -7.92%
Operating Cash Flow Q/Q Growth		 0.00% -137.49% 36.48%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% -66.98%
Profitability Metrics		 - - -
Gross Margin		 -750.84% 0.00% 0.00%
EBITDA Margin		 -2,641.86% 0.00% 0.00%
Operating Margin		 -2,563.50% 0.00% 0.00%
EBIT Margin		 -2,848.94% 0.00% 0.00%
Profit (Net Income) Margin		 -2,909.12% 0.00% 0.00%
Tax Burden Percent		 102.12% 100.00% 98.86%
Interest Burden Percent		 100.00% 98.69% 96.22%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 530.39% -116.80% -132.56%
Cash Return on Invested Capital (CROIC)		 0.00% -756.24% -1,160.78%
Operating Return on Assets (OROA)		 -56.10% 0.00% 0.00%
Return on Assets (ROA)		 -57.28% 0.00% 0.00%
Return on Common Equity (ROCE)		 530.39% -116.80% -132.56%
Return on Equity Simple (ROE_SIMPLE)		 530.39% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.26 -4.15 -6.80
NOPAT Margin		 -1,794.45% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1,173.90% -34.93% -37.14%
Return On Investment Capital (ROIC_SIMPLE)		 327.16% -39.85% -196.48%
Cost of Revenue to Revenue		 850.84% 0.00% 0.00%
SG&A Expenses to Revenue		 1,028.75% 0.00% 0.00%
R&D to Revenue		 752.80% 0.00% 0.00%
Operating Expenses to Revenue		 1,812.67% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.00 -5.94 -9.63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.85 -5.73 -9.39
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 10.39 26.89
Price to Tangible Book Value (P/TBV)		 0.00 10.39 26.89
Price to Revenue (P/Rev)		 214.07 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 140.53 209.27
Enterprise Value to Revenue (EV/Rev)		 213.13 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.02
Long-Term Debt to Equity		 0.00 0.00 0.02
Financial Leverage		 0.17 -0.98 -0.92
Leverage Ratio		 -9.26 1.65 1.38
Compound Leverage Factor		 -9.26 1.63 1.32
Debt to Total Capital		 0.00% 0.00% 1.86%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 1.86%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 98.14%
Debt to EBITDA		 0.00 0.00 -0.01
Net Debt to EBITDA		 0.00 0.00 0.32
Long-Term Debt to EBITDA		 0.00 0.00 -0.01
Debt to NOPAT		 0.00 0.00 -0.01
Net Debt to NOPAT		 0.00 0.00 0.44
Long-Term Debt to NOPAT		 0.00 0.00 -0.01
Altman Z-Score		 -2.35 22.95 11.50
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 0.50 8.12 2.51
Quick Ratio		 0.03 7.29 1.94
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5.30 -6.52
Operating Cash Flow to CapEx		 -409.01% -2,145.45% -3,826.60%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.02 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.09 0.00 0.00
Accounts Payable Turnover		 0.85 3.11 3.37
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 430.35 117.48 108.40
Cash Conversion Cycle (CCC)		 -430.35 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -0.45 0.70 0.42
Invested Capital Turnover		 -0.16 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.15 -0.28
Enterprise Value (EV)		 15 99 88
Market Capitalization		 15 108 91
Book Value per Share		 ($0.06) $1.67 $0.41
Tangible Book Value per Share		 ($0.06) $1.67 $0.41
Total Capital		 -0.38 10 3.46
Total Debt		 0.00 0.00 0.06
Total Long-Term Debt		 0.00 0.00 0.06
Net Debt		 -0.07 -9.72 -2.97
Capital Expenditures (CapEx)		 0.29 0.40 0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.27 -0.23 -0.67
Debt-free Net Working Capital (DFNWC)		 -1.20 9.49 2.37
Net Working Capital (NWC)		 -1.20 9.49 2.37
Net Nonoperating Expense (NNE)		 0.78 1.71 2.36
Net Nonoperating Obligations (NNO)		 -0.07 -9.72 -2.97
Total Depreciation and Amortization (D&A)		 0.15 0.21 0.24
Debt-free, Cash-free Net Working Capital to Revenue		 -1,809.95% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 -1,715.00% 0.00% 0.00%
Net Working Capital to Revenue		 -1,715.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.89) ($1.09)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 6.56M 8.38M
Adjusted Diluted Earnings per Share		 $0.00 ($0.89) ($1.09)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 6.56M 8.38M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 8.37M 8.48M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.26 -4.15 -6.80
Normalized NOPAT Margin		 -1,794.45% 0.00% 0.00%
Pre Tax Income Margin		 -2,848.79% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for eXoZymes

This table displays calculated financial ratios and metrics derived from eXoZymes' official financial filings.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 0.00 0.00 0.00 6,252,349.00 8,367,810.00 8,367,810.00 8,387,250.00 8,387,250.00 8,478,992.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 6,252,349.00 8,367,810.00 8,367,810.00 8,387,250.00 8,387,250.00 8,478,992.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 -0.29 -0.22 -0.28 -0.27 -0.32 -0.28
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 0.00% 0.00% -199.14% 0.00% -97.50% -86.72% -46.90% -36.56% -22.61%
EBIT Growth		 0.00% 0.00% 0.00% -209.59% 0.00% -93.44% -83.41% -45.57% -35.91% -22.21%
NOPAT Growth		 0.00% 0.00% 0.00% -311.32% 0.00% -93.44% -91.78% -56.49% -35.91% -22.36%
Net Income Growth		 0.00% 0.00% 0.00% -218.17% 0.00% -84.09% -73.48% -38.07% -44.61% -27.68%
EPS Growth		 0.00% 0.00% 0.00% -237.50% 0.00% -37.50% -27.27% 0.00% -33.33% -27.27%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% -628.67% -503.11% 39.40% -242.87% 65.42% -34.49%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -354.14% 0.00% 17.20%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 133.35% -39.79% -63.16%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -32.84% -22.26% -23.88% 1.84% -25.59% 3.81% -15.17% 11.87%
EBIT Q/Q Growth		 0.00% 0.00% -31.75% -21.31% -23.06% 1.64% -24.92% 3.72% -14.89% 11.56%
NOPAT Q/Q Growth		 0.00% 0.00% -31.75% -21.31% -23.06% 1.64% -30.62% 1.01% -6.87% 11.45%
Net Income Q/Q Growth		 0.00% 0.00% -34.91% -21.74% -10.84% -1.11% -27.14% 3.11% -16.09% 10.73%
EPS Q/Q Growth		 0.00% 0.00% -37.50% -22.73% 11.11% 8.33% -27.27% 3.57% -18.52% 12.50%
Operating Cash Flow Q/Q Growth		 0.00% 135.90% -1,002.49% 78.66% -953.97% 80.14% -35.68% -20.72% -6.31% 22.77%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% -22.17% -224.45% 76.63% 10.61%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 118.29% -47.23% -9.01% 279.71% -66.98% -67.71%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.16% 100.00% 99.88% 100.00% 100.00% 100.00% 96.19% 100.00%
Interest Burden Percent		 100.00% 100.00% 102.24% 102.77% 92.68% 95.17% 96.86% 97.48% 102.40% 99.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 0.00% -116.80% -75.54% -106.54% -940.69% -132.56% -185.84%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -756.24% 0.00% 0.00% 0.00% -1,160.78% -2,713.83%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 0.00% -116.80% -75.54% -106.54% -940.69% -132.56% -185.84%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.27 -0.71 -0.93 -1.13 -1.39 -1.37 -1.78 -1.77 -1.89 -1.67
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -451.55% -4.61% -11.54% -16.72% -24.09% -12.10% -14.12%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 31.33% -13.32% -15.37% -24.36% -27.68% -54.51% -105.69%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -0.52 -1.01 -1.33 -1.61 -1.98 -1.95 -2.44 -2.35 -2.70 -2.38
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.52 -0.96 -1.27 -1.56 -1.93 -1.89 -2.38 -2.29 -2.63 -2.32
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 10.39 9.85 11.44 22.52 26.89 41.57
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 10.39 9.85 11.44 22.52 26.89 41.57
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 140.53 213.24 225.25 91.42 209.27 455.63
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.19 0.02 0.03
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.19 0.02 0.03
Financial Leverage		 0.00 0.00 0.00 0.07 -0.93 -0.96 -0.95 -2.44 -0.92 -0.95
Leverage Ratio		 0.00 0.00 0.00 -0.99 1.65 1.30 1.34 6.36 1.38 1.49
Compound Leverage Factor		 0.00 0.00 0.00 -1.02 1.53 1.24 1.30 6.20 1.41 1.48
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.19% 15.73% 1.86% 3.34%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.19% 15.73% 1.86% 3.34%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 98.81% 84.27% 98.14% 96.66%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.11 -0.01 -0.01
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.88 0.47 0.32 0.14
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.11 -0.01 -0.01
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 -0.16 -0.01 -0.01
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 1.22 0.65 0.44 0.20
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 -0.16 -0.01 -0.01
Altman Z-Score		 0.00 0.00 0.00 0.00 23.95 18.44 17.96 27.30 15.33 5.32
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 0.25 8.12 6.52 6.19 4.53 2.51 1.32
Quick Ratio		 0.00 0.00 0.00 0.04 7.29 5.89 5.74 4.12 1.94 0.91
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 2.71 0.00 -1.74 -2.12 -6.88 -1.61 -1.44
Operating Cash Flow to CapEx		 0.00% 188.97% -6,815.26% 0.00% -2,712.63% -3,651.14% -3,041.15% -13,949.72% -2,632.15% -2,646.42%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 3.11 2.57 3.32 3.74 3.37 3.34
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 117.48 142.17 109.97 97.66 108.40 109.23
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -3.84 0.70 0.37 0.34 1.28 0.42 0.14
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 -3.84 0.00 0.37 0.34 5.11 -0.28 -0.23
Enterprise Value (EV)		 0.00 0.00 0.00 15 99 79 76 117 88 62
Market Capitalization		 0.00 15 15 15 108 87 83 121 91 64
Book Value per Share		 $0.00 $0.00 $0.00 ($0.58) $1.67 $1.42 $0.86 $0.64 $0.41 $0.18
Tangible Book Value per Share		 $0.00 $0.00 $0.00 ($0.58) $1.67 $1.42 $0.86 $0.64 $0.41 $0.18
Total Capital		 0.00 0.00 0.00 -3.60 10 8.88 7.32 6.38 3.46 1.58
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.09 1.00 0.06 0.05
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.09 1.00 0.06 0.05
Net Debt		 0.00 0.00 0.00 -0.23 -9.72 -8.51 -6.90 -4.10 -2.97 -1.39
Capital Expenditures (CapEx)		 0.00 0.15 0.04 0.00 0.21 0.03 0.05 0.01 0.07 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -4.61 -0.23 -0.54 -0.67 -0.73 -0.67 -0.94
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 -4.38 9.49 7.97 6.31 4.37 2.37 0.51
Net Working Capital (NWC)		 0.00 0.00 0.00 -4.38 9.49 7.97 6.31 4.37 2.37 0.51
Net Nonoperating Expense (NNE)		 0.25 0.30 0.43 0.53 0.45 0.49 0.58 0.52 0.77 0.70
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -0.23 -9.72 -8.51 -6.90 -4.10 -2.97 -1.39
Total Depreciation and Amortization (D&A)		 0.00 0.05 0.05 0.05 0.05 0.06 0.06 0.06 0.06 0.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.27) ($0.24) ($0.22) ($0.28) ($0.27) ($0.32) ($0.28)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 6.25M 6.56M 8.37M 8.38M 8.39M 8.38M 8.46M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.27) ($0.24) ($0.22) ($0.28) ($0.27) ($0.32) ($0.28)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 6.25M 6.56M 8.37M 8.38M 8.39M 8.38M 8.46M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 6.25M 8.37M 8.37M 8.39M 8.39M 8.48M 8.48M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.27 -0.71 -0.93 -1.13 -1.39 -1.37 -1.78 -1.77 -1.89 -1.67
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

eXoZymes (NASDAQ: EXOZ) remains a pre-revenue company with a long operating runway challenge, but its recent quarterly results show some important shifts in liquidity, spending, and balance sheet structure that investors should watch closely.

  • Cash improved sequentially from Q4 2025 to Q1 2026 to $1.44 million from $5.10 million, though the overall trend is still sharply lower than a year ago.
  • Operating cash outflow improved in Q1 2026 to $1.52 million from $1.97 million in Q4 2025, suggesting some moderation in cash burn.
  • Net loss narrowed year over year to $2.37 million in Q1 2026 from $2.66 million in Q4 2025 and $1.86 million in Q1 2025 on a quarterly basis the year before.
  • R&D spending stepped down to $1.12 million in Q1 2026 from $1.11 million in Q4 2025 and $1.22 million in Q3 2025, showing somewhat tighter expense control versus recent periods.
  • Interest and other income provided a small offset, helping reduce pre-tax losses in Q1 2026.
  • The company still generates no revenue, so all results remain dependent on financing and expense management rather than commercial sales.
  • Shares outstanding remain elevated at about 8.46 million basic shares in Q1 2026, with dilution risk still relevant if additional capital is raised.
  • Balance sheet equity remains positive at $1.53 million, but that cushion is much thinner than prior quarters.
  • Working capital weakened meaningfully as current assets fell to $2.09 million in Q1 2026 from $5.61 million in Q3 2025 and $7.53 million in Q2 2025.
  • Cash declined dramatically over the past year, dropping from $8.51 million in Q1 2025 to $1.44 million in Q1 2026.
  • Liabilities rose relative to assets: total liabilities were $2.49 million versus total assets of $4.02 million in Q1 2026, leaving only a modest equity base.
  • Retained earnings remain deeply negative at $(23.47) million, reflecting ongoing cumulative losses.

Bottom line: eXoZymes is still in an early, cash-consuming phase with no revenue and persistent losses. The good news is that quarterly operating cash burn and net loss improved somewhat in Q1 2026, but the company’s much lower cash balance means liquidity remains the main issue for investors. Until revenue emerges or financing improves the runway, the stock likely remains highly speculative.

07/17/26 01:06 PM ETAI Generated. May Contain Errors.

eXoZymes Financials - Frequently Asked Questions

According to the most recent income statement we have on file, eXoZymes' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

eXoZymes' net income appears to be on an upward trend, with a most recent value of -$9.16 million in 2025, rising from -$2.04 million in 2023. The previous period was -$5.86 million in 2024. View eXoZymes' forecast to see where analysts expect eXoZymes to go next.

eXoZymes' total operating income in 2025 was -$9.72 million, based on the following breakdown:
  • Total Gross Profit: -$3.64 million
  • Total Operating Expenses: $6.08 million

Over the last 2 years, eXoZymes' total revenue changed from $70.07 thousand in 2023 to $0.00 in 2025, a change of -100.0%.

eXoZymes' total liabilities were at $2.57 million at the end of 2025, a 1.5% decrease from 2024, and a 34.7% decrease since 2023.

In the past 2 years, eXoZymes' cash and equivalents has ranged from $66.53 thousand in 2023 to $9.72 million in 2024, and is currently $3.04 million as of their latest financial filing in 2025.

Over the last 2 years, eXoZymes' book value per share changed from -0.06 in 2023 to 0.41 in 2025, a change of -758.5%.


Related Companies

Financial statements for NASDAQ:EXOZ last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel